Navigation Links
Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
Date:11/9/2007

s well tolerated in combination with SLE standard- of-care therapy during long-term exposure, with incidence rates of adverse events, serious adverse events, malignancies, infections and laboratory abnormalities remaining comparable to placebo or decreasing through 2.5 years of treatment (Merrill et al).

"The results through 2.5 years confirm and extend the results reported at Weeks 52 and 76," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "At Week 52 in LymphoStat-B patients with active SLE, we saw significant reductions in SLE disease activity versus placebo as measured by the SELENA SLEDAI and BILAG indices, the Physician's Global Assessment, and, most importantly, by the response rate chosen as the primary efficacy endpoint of the Phase 3 trials. We are encouraged by the continued improvement in these patients, and by the improvement over time in patients crossing over from placebo to LymphoStat-B after 52 weeks. If the Phase 2 results are confirmed in our ongoing Phase 3 trials, we believe that LymphoStat-B could represent a breakthrough in the treatment of SLE."

The primary objectives of the Phase 2 study were to evaluate the efficacy and safety of LymphoStat-B (belimumab) plus standard of care, versus placebo plus standard of care. A total of 449 patients with active SLE were randomized to receive one of three different doses of LymphoStat-B or placebo (1, 4 or 10 mg/kg) administered intravenously over a 52-week treatment period, in addition to standard-of-care therapy. At the end of 52 weeks, 345 patients chose to participate in an optional 24-week extension phase of the study, during which all patients received LymphoStat-B. At Week 76, 296 patients chose to remain on LymphoStat-B treatment in an open-label long-term continuation phase of the Phase 2 trial, in which all patients are receiving 10 mg/kg LymphoStat-B. As of October 1, 2007, 244 patients remained on LymphoStat-B treatment in the continuation stu
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
(Date:8/28/2015)... FARUM, Denmark and ATLANTA ... July 31, 2015 the US Food and Drug Administration (FDA) ... Major Depressive Disorder in adult patients who have failed to ... episode. TMS is a non-invasive technique for stimulating neural tissue ... from Major Depressive Disorder. The procedure has been proven safe ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... wound center management, Decatur County Memorial Hospital recently transitioned management companies to partner ... Wound Center Management for their outpatient wound center. , Transitioning wound care ...
(Date:8/28/2015)... ... 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn ... applying for, they are unable to pass the initial drug test and therefore unable ... in order to be able to hire long-term, skilled talent. (1) Will Wesch, Director ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in ... Foundation has added yet another accolade to its cadre of widespread support—an official letter ... “With the help of the medical community and the University of Illinois at Chicago’s ...
(Date:8/28/2015)... ... , ... Saint Petersburg, FL —Pocket Protein™, a protein beverage ... gluten, lactose or caffeine in a convenient 2 oz. pouch that never needs ... Awards. , Five consumer packaged goods (CPG) products were selected by the SupplySide ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... FRANCISCO A further analysis of a previously published ... study of children with mild persistent asthma reports the ... children with differing demographic and clinical characteristics. ... in the TReating Children to Prevent Exacerbations of Asthma ...
... flu shot during pregnancy provides unanticipated benefits to the ... study examining the issue. Specifically, the study showed that ... significantly reduced risk of stillbirth, preterm birth and extremely ... Hospital Research Institute (OHRI), the CHEO Research Institute and ...
... , MONDAY, May 21 (HealthDay News) -- In a scenario ... found a way to perform nearly surgery-free gastric bypass procedures ... done with moveable magnets, is completed in less than a ... leaving behind any foreign material. Although pigs may not ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... used in some artificial sweeteners, may worsen Crohn,s disease by ... intestine, a new study suggests. However, researchers stressed that ... the lab, not in people, so it,s too soon to ...
... including a scientist from the Viral Immunology Center at ... herpesvirus infection of the eye is associated with neovascular ... in the elderly. The scientists found that human ... vascular endothelial growth factor, or VEGF, a signal protein ...
... to see that University of Cincinnati design students Alex Broerman ... design and prototype for a prescription-medicine pill bottle that better ... means of a simple and inexpensive innovation. In fact, ... their design a design intended to have universal appeal ...
Cached Medicine News:Health News:Baseline characteristics of children with mild persistent asthma predict response to ICS 2Health News:Flu shot during pregnancy shows unexpected benefits in large study 2Health News:Moveable Magnets Used to Forge Gastric Bypass in Pigs 2Health News:Moveable Magnets Used to Forge Gastric Bypass in Pigs 3Health News:Could Compound in Artificial Sweeteners Worsen Crohn's Disease? 2Health News:Could Compound in Artificial Sweeteners Worsen Crohn's Disease? 3Health News:Type of viral infection of eye associated with disease causing blindness in the elderly 2Health News:UC students design a better pill bottle for the blind and visually impaired 2Health News:UC students design a better pill bottle for the blind and visually impaired 3
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
... genuine BOOKWALTER™ Retractor System represents the ... design available. Its wide array of ... with a versatile system for multi-directional ... BOOKWALTER™ Kits are available for specific ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... Another breakthrough in real-time PCR analysis ... mutation analysis. ,The LightCycler 480 System ... and will meet the needs of ... in genomics research including array validation, ...
Medicine Products: